Research programme: CR1-targeted vaccines - Elusys Therapeutics
Latest Information Update: 14 Sep 2010
At a glance
- Originator Elusys Therapeutics
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Infections
Most Recent Events
- 14 Sep 2010 This programme is still in active development
- 06 Dec 2007 Early research in Infections in USA (Parenteral)